Latest News & Updates
Breaking News
4 hours ago
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Other trending news you may like to read
Recludix Pharma Achieves Biologic-Comparable Efficacy with Oral STAT6 Inhibitor REX-8756 in Atopic Dermatitis Preclinical Model
Recludix Pharma's oral STAT6 inhibitor REX-8756 matched biologic efficacy in preclinical atopic dermatitis models with a differentiated safety profile vs. JAK inhibitors.
Pharma Now Editorial Team
AstraZeneca Achieves Major Survival Gains with Imfinzi Regimens in Muscle-Invasive Bladder Cancer
AstraZeneca's Imfinzi delivers survival gains in muscle-invasive bladder cancer, with perioperative use raising supply and QA coordination demands.
Pharma Now Editorial Team
Telix Pharmaceuticals Signs Dual Collaboration Agreements with EDAP and Profound to Expand PSMA-PET Imaging into Ablative Prostate Cancer Workflows
Telix signs LOIs with EDAP and Profound to explore PSMA-PET imaging in HIFU and TULSA prostate cancer workflows, outside current approved indications.
Pharma Now Editorial Team
aTyr Pharma Secures FDA Type C Feedback, Plans June IND Filing for Efzofitimod Phase 3 Sarcoidosis Study
aTyr Pharma plans a June 2026 IND filing for an efzofitimod Phase 3 study in pulmonary sarcoidosis following FDA Type C meeting feedback on endpoint design.
Pharma Now Editorial Team
